DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
TAK-954 is an investigational drug.
There have been 333 clinical trials for TAK-954. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).
Recent Clinical Trials for TAK-954
|Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet||Takeda||Phase 2|
|A Study to Evaluate the Safety,Tolerability, and Pharmacokinetics (PK) of TAK-951 in Healthy Participants Following Intravenous Administration||Takeda||Phase 1|
|A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants||Takeda||Phase 1|